Evaluation of the Effect of Mesenchymal Stem Cells on Breast Cancer Migration and Metastasis: A Systematic Review and Meta-analysis

Document Type : Review Article


1 JKKM College of Pharmacy, Tamil Nadu Dr. M.G.R Medical University, Tamil Nadu, India

2 Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

3 Department of Pharmacology and Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran


Background and aim: Insufficient evidence in the field of the effect of MSCs on the migration of breast cancer cells caused the present study to be conducted with the consensus of the findings and to perform a meta-analysis to evaluate the effect of mesenchymal stem cells on breast cancer migration and metastasis.
Material and methods: In the present systematic review and meta-analysis, information about mesenchymal stem cells in breast cancer patients in all articles published until the end of July 2023 through searching in databases PubMed, Scopus, Science Direct, ISI, Web of Knowledge, Elsevier, Wiley, and Embase and Google Scholar search engine were extracted using keywords and their combinations by two trained researchers independently. Data analysis was done using the fixed effects model in the meta-analysis by STATA (version 17); a p-value less than 0.05 was considered significant.
Results: Thirteen in-vitro and in-vivo studies were included in the meta-analysis process. The risk ratio of incidence of metastasis after MSCs administration was 7.37 (RR, 95% CI: 7.23, 7.53; I2 =99.86% (p=0.00), very high heterogeneity); human-MSCs from different sources appear to increase the migratory activity of MDA-MB-231 cells and MCF-7 cells compared to control group(p<0.01). 
Conclusions: Meta-analysis showed that MSCs are significantly effective in increasing the migration of breast cancer cells and metastasis. Therefore, MSCs can be a promising option for treating breast cancer metastases.


Main Subjects

[1] Watkins EJ. Overview of breast cancer. Journal of the American Academy of PAs. 2019;32(10):13-7.
[2] Lima SM, Kehm RD, Terry MB. Global breast cancer incidence and mortality trends by region, age-groups, and fertility patterns. EClinicalMedicine. 2021;38. https://doi.org/10.1016/j.eclinm.2021.100985.
[3] Cortes-Guiral D, Huebner M, Alyami M, Bhatt A, Ceelen W, Glehen O, et al. Primary and metastatic peritoneal surface malignancies. Nature Reviews Disease Primers. 2021;7(1):91. https://doi.org/10.1038/s41572-021-00326-6.
[4] Mathan SV, Rajput M, Singh RP. Chemotherapy and radiation therapy for cancer. InUnderstanding Cancer 2022:217-36. https://doi.org/10.1016/B978-0-323-99883-3.00003-2.
[5] Debela DT, Muzazu SG, Heraro KD, Ndalama MT, Mesele BW, Haile DC, et al. New approaches and procedures for cancer treatment: Current perspectives. SAGE open medicine. 2021:20503121211034366. https://doi.org/10.1177/20503121211034366.
[6] Jahanafrooz Z, Mosafer J, Akbari M, Hashemzaei M, Mokhtarzadeh A, Baradaran B. Colon cancer therapy by focusing on colon cancer stem cells and their tumor microenvironment. Journal of cellular physiology. 2020;235(5):4153-66. https://doi.org/10.1002/jcp.29337.
[7] Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, Capilla-Gonzalez V. Therapeutic potential of mesenchymal stem cells for cancer therapy. Frontiers in bioengineering and biotechnology. 2020;8:43. https://doi.org/10.3389/fbioe.2020.00043.
[8] Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell proliferation. 2020;53(1):e12712. https://doi.org/10.1111/cpr.12712.
[9] Ma J, Yong L, Lei P, Li H, Fang Y, Wang L, et al. Advances in microRNA from adipose-derived mesenchymal stem cell-derived exosome: focusing on wound healing. Journal of Materials Chemistry B. 2022;10(46):9565-77. https://doi.org/10.1039/D2TB01987F.
[10] Wang Y, Fang J, Liu B, Shao C, Shi Y. Reciprocal regulation of mesenchymal stem cells and immune responses. Cell Stem Cell. 2022;29(11):1515-30. https://doi.org/10.1016/j.stem.2022.10.001.
[11] Han Y, Yang J, Fang J, Zhou Y, Candi E, Wang J, et al. The secretion profile of mesenchymal stem cells and potential applications in treating human diseases. Signal Transduction and Targeted Therapy. 2022;7(1):92. https://doi.org/10.1038/s41392-022-00932-0.
[12] Fu X, Liu G, Halim A, Ju Y, Luo Q, Song G. Mesenchymal stem cell migration and tissue repair. Cells. 2019;8(8):784. https://doi.org/10.3390/cells8080784.
[13] Huang YZ, Gou M, Da LC, Zhang WQ, Xie HQ. Mesenchymal stem cells for chronic wound healing: current status of preclinical and clinical studies. Tissue Engineering Part B: Reviews. 2020;26(6):555-70. https://doi.org/10.1089/ten.teb.2019.0351.
[14] Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Advanced Science. 2021;8(7):2002944. https://doi.org/10.1002/advs.202002944.
[15] Alessandrini M, Preynat-Seauve O, De Bruin K, Pepper MS. Stem cell therapy for neurological disorders. South African Medical Journal. 2019;109(8 Supplement 1):S71-8.
[16] Nasser MI, Masood M, Adlat S, Gang D, Zhu S, Li G, et al. Mesenchymal stem cell-derived exosome microRNA as therapy for cardiac ischemic injury. Biomedicine & Pharmacotherapy. 2021;143:112118. https://doi.org/10.1016/j.biopha.2021.112118.
[17] Razeghian-Jahromi I, Matta AG, Canitrot R, Zibaeenezhad MJ, Razmkhah M, Safari A, Nader V, et al. Surfing the clinical trials of mesenchymal stem cell therapy in ischemic cardiomyopathy. Stem Cell Research & Therapy. 2021;12(1):361. https://doi.org/10.1186/s13287-021-02443-1.
[18] Xiong J, Hu H, Guo R, Wang H, Jiang H. Mesenchymal stem cell exosomes as a new strategy for the treatment of diabetes complications. Frontiers in Endocrinology. 2021;12:646233. https://doi.org/10.3389/fendo.2021.646233.
[19] Qi Y, Ma J, Li S, Liu W. Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. Stem cell research & therapy. 2019;10(1):1-13.
[20] Kangari P, Talaei-Khozani T, Razeghian-Jahromi I, Razmkhah M. Mesenchymal stem cells: amazing remedies for bone and cartilage defects. Stem Cell Research & Therapy. 2020;11(1):1-21.
[21] López de Andrés J, Griñán-Lisón C, Jiménez G, Marchal JA. Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. Journal of hematology & oncology. 2020;13(1):1-22.
[22] Atiya H, Frisbie L, Pressimone C, Coffman L. Mesenchymal stem cells in the tumor microenvironment. Tumor Microenvironment: Non-Hematopoietic Cells. 2020:31-42. https://doi.org/10.1007/978-3-030-37184-5_3.
[23] He Z, Li W, Zheng T, Liu D, Zhao S. Human umbilical cord mesenchymal stem cells-derived exosomes deliver microRNA-375 to downregulate ENAH and thus retard esophageal squamous cell carcinoma progression. Journal of experimental & clinical cancer research. 2020;39(1):1-8.
[24] Arneth B. Tumor microenvironment. Medicina. 2019;56(1):15. https://doi.org/10.3390/medicina56010015.
[25] OHAT N. OHAT risk of bias rating tool for human and animal studies. US Department of Health and Human Services. 2015.
[26] Zhou X, Li T, Chen Y, Zhang N, Wang P, Liang Y, et al. Mesenchymal stem cell‑derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway. International journal of oncology. 2019;54(5):1843-52. https://doi.org/10.3892/ijo.2019.4747.
[27] Chen Y, He Y, Wang X, Lu F, Gao J. Adipose‑derived mesenchymal stem cells exhibit tumor tropism and promote tumorsphere formation of breast cancer cells. Oncology reports. 2019;41(4):2126-36. https://doi.org/10.3892/or.2019.7018.
[28] Wu S, Wang Y, Yuan Z, Wang S, Du H, Liu X, et al. Human adipose‑derived mesenchymal stem cells promote breast cancer MCF7 cell epithelial‑mesenchymal transition by cross interacting with the TGF‑β/Smad and PI3K/AKT signaling pathways. Molecular medicine reports. 2019;19(1):177-86. https://doi.org/10.3892/mmr.2018.9664.
[29] Alshareeda AT, Rakha E, Alghwainem A, Alrfaei B, Alsowayan B, Albugami A, et al. The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks. PLoS One. 2018;13(11):e0207593. https://doi.org/10.1371/journal.pone.0207593.
[30] Koellensperger E, Bonnert LC, Zoernig I, Marmé F, Sandmann S, Germann G, et al. The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction. Stem cell research & therapy. 2017;8(1):1-9.
[31] Li TA, Zhang C, Ding Y, Zhai WE, Liu KU, Bu FA, et al. Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway. Oncology reports. 2015;34(3):1469-77. https://doi.org/10.3892/or.2015.4109.
[32] Zhang C, Zhai WE, Xie YA, Chen Q, Zhu WE, Sun X. Mesenchymal stem cells derived from breast cancer tissue promote the proliferation and migration of the MCF‑7 cell line in vitro. Oncology letters. 2013;6(6):1577-82. https://doi.org/10.3892/ol.2013.1619.
[33] Jayaraman H, Anandhapadman A, Ghone NV. In Vitro and In Vivo Comparative Analysis of Differentially Expressed Genes and Signaling Pathways in Breast Cancer Cells on Interaction with Mesenchymal Stem Cells. Applied Biochemistry and Biotechnology. 2023;195(1):401-31. https://doi.org/10.1007/s12010-022-04119-9.
[34] Gonzalez ME, Martin EE, Anwar T, Arellano-Garcia C, Medhora N, Lama A, et al. Mesenchymal stem cell-induced DDR2 mediates stromal-breast cancer interactions and metastasis growth. Cell reports. 2017;18(5):1215-28. http://dx.doi.org/10.1016/j.celrep.2016.12.079.
[35] Meleshina AV, Cherkasova EI, Shirmanova MV, Klementieva NV, Kiseleva EV, Snopova LВ, et al. Influence of mesenchymal stem cells on metastasis development in mice in vivo. Stem cell research & therapy. 2015;6:1-10. https://doi.org/10.1186/s13287-015-0003-7.
[36] Lacerda L, Debeb BG, Smith D, Larson R, Solley T, Xu W, et al. Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Research. 2015;17:1-7. https://doi.org/10.1186/s13058-015-0549-4.
[37] Ma F, Chen D, Chen F, Chi Y, Han Z, Feng X, et al. Human umbilical cord mesenchymal stem cells promote breast cancer metastasis by interleukin-8-and interleukin-6-dependent induction of CD44+/CD24-cells. Cell transplantation. 2015;24(12):2585-99. https://doi.org/10.3727/096368915X687462.
[38] Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M. Human bone marrow–derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Cancer research. 2010;70(24):10044-50. https://doi.org/10.1158/0008-5472.CAN-10-1254.
[39] Kamat P, Schweizer R, Kaenel P, Salemi S, Calcagni M, Giovanoli P, et al. Human adipose-derived mesenchymal stromal cells may promote breast cancer progression and metastatic spread. Plastic and reconstructive surgery. 2015;136(1):76-84. https://doi.org/10.1097/PRS.0000000000001321.
[40] Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S, et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunology letters. 2009;126(1-2):37-42. https://doi.org/10.1016/j.imlet.2009.07.010.
[41] Cheng HY, Ghetu N, Wallace CG, Wei FC, Liao SK. The impact of mesenchymal stem cell source on proliferation, differentiation, immunomodulation and therapeutic efficacy. J Stem Cell Res Ther. 2014;4(10):1-8. http://dx.doi.org/10.4172/2157-7633.1000237.
[42] Shangguan L, Ti X, Krause U, Hai B, Zhao Y, Yang Z, et al. Inhibition of TGF-β/Smad signaling by BAMBI blocks differentiation of human mesenchymal stem cells to carcinoma-associated fibroblasts and abolishes their protumor effects. Stem cells. 2012;30(12):2810-19. https://doi.org/10.1002/stem.1251.
[43] Mi Z, Bhattacharya SD, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin promotes CCL5-mesenchymal stromal cell-mediated breast cancer metastasis. Carcinogenesis. 2011;32(4):477-87. https://doi.org/10.1093/carcin/bgr009.